US Bancorp DE Reduces Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

US Bancorp DE lowered its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 54.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,621 shares of the biopharmaceutical company's stock after selling 4,330 shares during the period. US Bancorp DE's holdings in Intra-Cellular Therapies were worth $302,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after purchasing an additional 2,157 shares during the last quarter. Barclays PLC raised its holdings in Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after purchasing an additional 25,435 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Intra-Cellular Therapies by 31.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock worth $33,258,000 after purchasing an additional 109,892 shares in the last quarter. Oak Ridge Investments LLC lifted its position in shares of Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after buying an additional 8,440 shares during the last quarter. Finally, Cynosure Group LLC boosted its holdings in shares of Intra-Cellular Therapies by 161.0% in the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company's stock valued at $1,057,000 after buying an additional 8,909 shares in the last quarter. 92.33% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Mizuho cut shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a "buy" rating to a "hold" rating and raised their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 price objective (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Finally, Baird R W cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Ten analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of "Hold" and an average price target of $106.08.

Intra-Cellular Therapies Stock Up 0.1 %

Shares of Intra-Cellular Therapies stock traded up $0.19 during trading on Monday, reaching $131.45. The company's stock had a trading volume of 996,758 shares, compared to its average volume of 1,326,064. The business has a 50 day moving average price of $123.95 and a 200-day moving average price of $95.70. The company has a market capitalization of $13.98 billion, a P/E ratio of -151.09 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 12-month low of $63.87 and a 12-month high of $131.46.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.